Tango Therapeutics Announces CMO Departure, Director Changes
Ticker: TNGX · Form: 8-K · Filed: Aug 25, 2025 · CIK: 1819133
Sentiment: neutral
Topics: executive-departure, board-changes, compensation
TL;DR
Tango Therapeutics' CMO is out, new directors in. Keep an eye on who replaces her and the new board's strategy.
AI Summary
Tango Therapeutics, Inc. announced on August 21, 2025, the departure of its Chief Medical Officer, Dr. Barbara N. Weber. The company also reported on compensatory arrangements for its named executive officers and the election of new directors. The filing does not specify a replacement for Dr. Weber or details on the compensatory arrangements.
Why It Matters
The departure of a Chief Medical Officer can signal shifts in R&D strategy or pipeline progress, while director changes may indicate evolving governance or strategic direction.
Risk Assessment
Risk Level: medium — The departure of a key executive like the Chief Medical Officer can create uncertainty regarding the company's drug development pipeline and future strategy.
Key Players & Entities
- Tango Therapeutics, Inc. (company) — Registrant
- Dr. Barbara N. Weber (person) — Chief Medical Officer who departed
- August 21, 2025 (date) — Date of earliest event reported
- BCTG Acquisition Corp. (company) — Former company name
FAQ
Who has been appointed as the interim or permanent replacement for Dr. Barbara N. Weber as Chief Medical Officer?
The filing does not specify an interim or permanent replacement for Dr. Barbara N. Weber as Chief Medical Officer.
What were the specific reasons cited for Dr. Barbara N. Weber's departure?
The filing states that Dr. Barbara N. Weber's departure is effective as of August 21, 2025, but does not provide specific reasons for her departure.
Were there any changes to the Board of Directors announced in this filing?
Yes, the filing indicates the election of directors as part of the reported events.
What specific compensatory arrangements for certain officers are detailed in this filing?
The filing mentions compensatory arrangements of certain officers as an item of disclosure but does not provide specific details within the provided text.
What is Tango Therapeutics, Inc.'s primary business sector?
Tango Therapeutics, Inc. is in the Pharmaceutical Preparations sector, SIC code 2834.
Filing Stats: 402 words · 2 min read · ~1 pages · Grade level 13.2 · Accepted 2025-08-25 16:06:56
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share TNGX The Nasdaq Global Ma
Filing Documents
- d88761d8k.htm (8-K) — 20KB
- 0001193125-25-187680.txt ( ) — 131KB
- tngx-20250821.xsd (EX-101.SCH) — 3KB
- tngx-20250821_lab.xml (EX-101.LAB) — 18KB
- tngx-20250821_pre.xml (EX-101.PRE) — 11KB
- d88761d8k_htm.xml (XML) — 4KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 21, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 201 Brookline Avenue Suite 901 Boston , MA 02215 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: 857 - 320-4900 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share TNGX The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 21, 2025, Douglas Barry notified the board of directors of Tango Therapeutics, Inc. (the "Company") of his resignation as Chief Legal and Compliance Officer and Corporate Secretary of the Company, in each case, effective as of September 12, 2025, to pursue another opportunity. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 25, 2025 TANGO THERAPEUTICS, INC. By: /s/ Daniella Beckman Name: Daniella Beckman Title: Chief Financial Officer